Osteoclasts (OCs) are critical for calcium homeostasis and structural bone integrity, but their inappropriate activation is responsible for significant morbidity in many diseases, including osteoporosis, rheumatoid arthritis, and cancer metastasis to bone. RANKL mediates differentiation of macrophage lineage cells into OCs and induces NF-kappaB. There are 5 subunits in the NF-kappaB family (p65, RelB, c-rel, p50, and p52) each bearing the DNA-binding Rel homology domain, and transcription is mediated by homo-and -heterodimers. Activation of NF-kappaB occurs by two distinct routes. The classical pathway involves IkappaB kinase beta (IKKbeta)-dependent degradation of IkappaBalpha and rapid translocation of active NF-kappaB dimers, primarily p65/p50, into the nucleus. Additionally, phosphorylation and acetylation of p65 occur in a signal-dependent manner, and further modulate NF-kappaB activity. The alternative pathway is controlled by NIK which activates IKKalpha, prompting generation, from its precursor p100, of the active NF-kappaB subunit p52, which travels to the nucleus with RelB over several hours and remains for days. Thus, RANKL exposure leads to both acute and prolonged activation of NF-kappaB by stimulating the classical and alternative pathways, respectively, with each controlling different heterodimers. We find that lack p65, the key transducer of the classical pathway, leads to OC precursor apoptosis, in vitro, and a decreased OC response to RANKL, in vivo. In contrast, lack of RelB, the unique subunit of the alternative pathway, blocks OC differentiation, in vitro, and diminishes pathological bone resporption, in vivo, in the absence of apoptosis. Additionally, overexpression of one subunit cannot compensate for the absence of the other subunit, indicating distinct functions for these NF-kappaB subunits. We hypothesize that: 1) in vivo, p65 controls OC differentiation and survival, and RelB controls OC differentiation, 2) specific components of the transcriptional activation (TA) and Rel homology (RH) domains of p65 and RelB confer their distinct functions in OC survival and differentiation, 3) post- translational modifications of p65 (acetylation and phosphorylation) are critical for its function downstream of RANKL. We therefore propose to: 1) define the requirements for p65 and RelB in OC differentiation and survival, in vivo, by examining the basal and RANKL-stimulated bone phenotype in mice lacking p65 or RelB, 2) determine which components of the TA and RH domains of p65 and RelB confer their distinct functions on OC survival and differentiation, 3) define the post-translational p65 acetylation and phosphorylation events that are critical for its function downstream of RANKL. Because NF-kappaB is a target of existing drugs such as the proteosome inhibitor bortezomib, and other drugs currently in development, it is critically important to understand its specific pathways in physiological contexts such as bone. We expect that this study will contribute to better rational design of drugs to target specific pathophysiology.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Project (R01)
Project #
5R01AR052705-04
Application #
7676059
Study Section
Skeletal Biology Development and Disease Study Section (SBDD)
Program Officer
Sharrock, William J
Project Start
2006-09-15
Project End
2011-03-31
Budget Start
2009-09-01
Budget End
2011-03-31
Support Year
4
Fiscal Year
2009
Total Cost
$286,388
Indirect Cost
Name
Washington University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Briseño, Carlos G; Gargaro, Marco; Durai, Vivek et al. (2017) Deficiency of transcription factor RelB perturbs myeloid and DC development by hematopoietic-extrinsic mechanisms. Proc Natl Acad Sci U S A 114:3957-3962
Mbalaviele, Gabriel; Novack, Deborah V; Schett, Georg et al. (2017) Inflammatory osteolysis: a conspiracy against bone. J Clin Invest 127:2030-2039
Frederiksen, Anja L; Larsen, Martin J; Brusgaard, Klaus et al. (2016) Neonatal High Bone Mass With First Mutation of the NF-?B Complex: Heterozygous De Novo Missense (p.Asp512Ser) RELA (Rela/p65). J Bone Miner Res 31:163-72
Novack, Deborah Veis; Mbalaviele, Gabriel (2016) Osteoclasts-Key Players in Skeletal Health and Disease. Microbiol Spectr 4:
Capietto, Aude-Hélène; Chan, Szeman Ruby; Ricci, Biancamaria et al. (2016) Novel ER? positive breast cancer model with estrogen independent growth in the bone microenvironment. Oncotarget 7:49751-49764
Novack, Deborah Veis (2016) Editorial: Inflammatory Osteoclasts: A Different Breed of Bone Eaters? Arthritis Rheumatol 68:2834-2836
Luo, Xianmin; Fu, Yujie; Loza, Andrew J et al. (2016) Stromal-Initiated Changes in the Bone Promote Metastatic Niche Development. Cell Rep 14:82-92
Pritchard, Zachary J; Cary, Rachel L; Yang, Chang et al. (2015) Inhibition of CaMKK2 reverses age-associated decline in bone mass. Bone 75:120-7
Qu, Chao; Bonar, Sheri L; Hickman-Brecks, Cynthia L et al. (2015) NLRP3 mediates osteolysis through inflammation-dependent and -independent mechanisms. FASEB J 29:1269-79
Decker, Corinne E; Yang, Zhengfeng; Rimer, Ryan et al. (2015) Tmem178 acts in a novel negative feedback loop targeting NFATc1 to regulate bone mass. Proc Natl Acad Sci U S A 112:15654-9

Showing the most recent 10 out of 33 publications